China NMPA Drug Inspection - Chongqing Jiang"anfang Pharmaceutical Co., Ltd. - Anti-cervicitis tablets

In December 2023, the National Medical Products Administration (NMPA) of China issued Announcement No. 65, identifying four batches of pharmaceutical products that failed to meet quality standards. The inspections, conducted by various provincial testing institutes, revealed specific violations across several entities. Chongqing Jiang'anfang Pharmaceutical Co., Ltd. produced Anti-Cervicitis Tablets that failed microbial limit tests, while Sinopharm Holding Tianhe Jilin Pharmaceutical Co., Ltd. was flagged for a batch of Tacrolimus Ointment with excessive related substances. Additionally, Chunyuantang Clinic and Nagqu Huimin Hospital were cited for issues with Fried Silkworm Powder (total ash content) and Prepared Licorice Root (content determination), respectively. Operating under the framework of the Drug Administration Law of the People's Republic of China, the NMPA has mandated immediate risk control measures. These actions require the involved companies to suspend the sale and use of the non-compliant batches and initiate product recalls. Furthermore, the organizations must investigate the root causes of these failures and implement corrective actions. Provincial regulators have also been instructed to pursue formal investigations into potential illegal activities and publicly disclose their findings to ensure pharmaceutical safety and compliance.